Although GI AEs are common across all GLP-1 RAs, differences in formulation, dosing, and dual agonism with tirzepatide can influence how well patients tolerate therapy
However, it can cause steatorrhea, resulting in fat-soluble vitamin deficiency, and can even cause liver damage
Peptide YY and other satiety peptides demonstrate clear physiological roles, with early failures attributable to rapid exposure and intolerance rather than to a lack of efficacy, again favoring re-evaluation
In contrast, a lack of sleep raises cortisol and inflammation, decreasing GLP-1 secretion and increasing hungermaking consistent, restorative sleep imperative for maintaining a healthy weight
Clinical trials such as the STEP programme (semaglutide) and SUSTAIN studies show that: Initial weeks : Modest weight loss primarily from reduced caloric intake Months 23 : More noticeable reduction becomes evident Months 36 : Continued steady weight loss as dose escalates Months 612 : Peak weight loss approaches, with most studies showing maximal effect by 1218 months It is important to recognise that GLP-1 medications require dose titration starting at a low dose and gradually increasing over several weeks according to the specific product's SmPC
